Forte Biosciences (FBRX)
76.99
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 4 Forte Biosciences, Inc. For: Aug 27 Filed by: Kornfeld Steven
August 27, 2026 4:36 PM - SEC Filing
Form 4 Forte Biosciences, Inc. For: Aug 27 Filed by: Brun Scott C.
August 27, 2026 4:35 PM - SEC Filing
Form 4 Forte Biosciences, Inc. For: Aug 27 Filed by: GRYSKA DAVID W
August 27, 2026 4:33 PM - SEC Filing
Form 4 Forte Biosciences, Inc. For: Aug 27 Filed by: VINCENT RICHARD G
August 27, 2026 4:32 PM - SEC Filing
Form 4 Forte Biosciences, Inc. For: Aug 27 Filed by: FINCK BARBARA K
August 27, 2026 4:32 PM - SEC Filing
Form 4 Forte Biosciences, Inc. For: Aug 27 Filed by: Kapoor Shivpreet Singh
August 27, 2026 4:31 PM - SEC Filing
Form 4 Forte Biosciences, Inc. For: Aug 27 Filed by: Doberstein Stephen K
August 27, 2026 4:30 PM - SEC Filing
Form 4 Forte Biosciences, Inc. For: Aug 27 Filed by: Riley Antony A
August 27, 2026 4:29 PM - SEC Filing
Form 4 Forte Biosciences, Inc. For: Aug 27 Filed by: Wagner Paul A.
August 27, 2026 4:28 PM - SEC Filing
argenx completes $77-per-share acquisition of Forte Biosciences
August 27, 2026 8:50 AM - StreetInsider
argenx Completes Acquisition of Forte Biosciences, Inc.
August 27, 2026 8:50 AM - StreetInsider
argenx launches $77-per-share tender offer for Forte Biosciences
August 6, 2026 7:49 AM - StreetInsider
Barclays Downgrades Forte Biosciences Inc. (FBRX) to Equalweight
July 28, 2026 3:34 AM - StreetInsider
Brookline Capital Markets Downgrades Forte Biosciences Inc. (FBRX) to Hold
July 27, 2026 11:30 AM - StreetInsider
Evercore ISI Downgrades Forte Biosciences Inc. (FBRX) to In Line
July 27, 2026 11:29 AM - StreetInsider
TD Cowen Downgrades Forte Biosciences Inc. (FBRX) to Hold
July 27, 2026 8:14 AM - StreetInsider
argenx to acquire Forte Biosciences for $2.2 billion
July 27, 2026 1:00 AM - StreetInsider
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
July 27, 2026 1:00 AM - StreetInsider
Full Article List
